How Natco Pharma put US drug giant Eli Lilly under pressure for COVID-19 drug through compulsory licensing filing

The Indian company says it has offered 7% royalty to the US drugmaker for Baricitinib. Natco has filed for compulsory licensing, arguing that Eli Lilly’s small distribution network won’t be able to serve India’s population and the 14-day, Rs 42,000 per-patient treatment regimen for the US drug is too expensive.

from Moneycontrol Business News https://ift.tt/3eY6yeS